medigraphic.com
Órgano Oficial de la Sociedad Mexicana de Angiología y Cirugía Vascular

2005, Number 2

<< Back Next >>

Rev Mex Angiol 2005; 33 (2)

Efficacy of Fabroven in acute hemorrhoidal disease treatment

Granados AJ, Chávez MC, López MA, Rodríguez VM, Yamamoto FK

Language: Spanish
References: 21
Page: 62-66
PDF size: 128.39 Kb.


ABSTRACT

Introduction: This article analyzes the treatment outcomes with Fabroven extract in 402 patients with acute hemorrhoidal disease (grade I, II and III), who were included in six different studies from European countries in the Mediterranean area.
Patients and methods: The patients were treated with three to twelve capsules of Fabroven, divided in three doses every 24 hours the first three days of treatment, and in some cases, four capsules divided in two doses thereafter. The studied symptoms were: painful symptoms (discomfort, sensation of heaviness, burning, pruritus, tenesmus), accompanying symptoms (rectal bleeding, altered intestinal motility, abdominal pain), local signs (prolapse, congestive state, inflammation) and over-all severity score of symptoms. Descriptive statistical analysis was used to evaluate all results.
Results: Data analysis showed a statistical significant decrease in all scores between zero and sev-en days. The therapeutic efficacy was proven in 90% of patients and only 5% reported some adverse reaction. The pain evaluation score showed a decrease of five points on the average (p ‹ 0.0001), while the functional symptoms decreased nine points, the local symptoms 3.5 points and finally the accompanying symptoms decreased 1.5 points (p ‹ 0.001).
Conclusion: The treatment with Fabroven decreases significantly the pain, functional symptoms and inflammation in hemorrhoidal crisis of patients with disease grade I, II and III.


REFERENCES

  1. Chevel B. Crise hémorroïdaire. Place de la thérapeutique veineuse. Médic Chirurg Digest 1979; 84: 365-9.

  2. Bouskela E, Cyrino F, Marcelon G. Effects of ruscus extract on the internal diameter of arterioles and venules of the hamster cheek pouch microcirculation. J Cardiovasc Pharmacol 1993; 22: 221-4.

  3. Bronco D, Osswald W. The influence of ruscus extract on the uptake and metabolism of noradrenaline in the normal and varicose human saphena veins. Phlébol 1988, 3: 33-9.

  4. Marcelon G, Pouget G, Tisne-Versaille J. Effect of ruscus on the adrenoceptors of the canine lymphatic thoracic duct. Phlébol 1998; 3 (Suppl. 1): 109-12.

  5. Bouskela, et al. Effects of Cyclo 3 Fort, Diosmin 300 mg and Venoruton Fort on microvascular reactivity in the hamster cheek pouch. Communication XXIXe Congrès du Collège Français de Pathologie Vasculaire; March 1995.

  6. Le Devehat C, et al. The effects of Cyclo 3 Fort treatment on hemorheological disturbances during a provoked venous stasis in patients with chronic venous insufficiency. Clinic Haemorheol 14 (Suppl. 1): 53-63.

  7. Baurain R, Dom G, Trouet A. Protecting effect of Cyclo 3 Fort and its constituents for human endothelial cells under hypoxia. Clinic Haemorheol 14 (Suppl. 1): 15-21.

  8. Mauss HJ. Von Wirkung .Ruscus extract bei der behandlung hämorrhoidaler Beschwerden. Phlebol 1992; 21: 200-4.

  9. Cope R, Laurent D, Cauquil J, Demarez JP. La crise hémorroidaire: efficacité de Cyclo 3 Fort. Impact Médicin 1988; 290: 1-4.

  10. Baujat JP, Demarez JP, Laurent D, Cauqil J. Objectivation de l’activité intrinsèque et de la tolérance clinique de Cyclo 3 versus placebo dans le traitement de la crise hémorroïdaire. La Gazette Medicale 1985; 92: 37.

  11. Baujat JP, Demarez JP, Bernard-Fernier MF, Laurent D, Cauquil J. Thérapeutique antihémorroïdaire: étude comparée de l’activité des rutosides et de Cyclo 3. La Gazette Médicale 1984; 91: 29.

  12. Poupon R. Étude de Cyclo 3 dans les affections vasculaires anales. Rev Franç Gastro Entérol 1978; 141: 58-62.

  13. Bennani A, Biadillah MC, Cherkaoui A, Sebti M. Acute attack of hemorrhoids: efficacy of Fabroven based on results in 124 cases reported by specialists. Phlébol 1999; 52: 83-93.

  14. Pathologie et thérapeutique hémorroïdaire: résultats d’une enquête effectuée auprès de 517 médecins généralistes. Documentation scientifique, Laboratoire Pierre-Fabre, 1992.

  15. De Paredes B, Demarez JP, Cauquil J. Analyse comparative des activités thérapeutiques de Cyclo 3 Fort et diosmine 450 mg associé à l’hesperidine 50 mg dans l’insuffisance veineuse des membres inférieurs. Étude en double insu auprès de 60 patients. Vie Médic 1990; 6: 226-32.

  16. Ledevehat C, Lemoine A, Roux E, et al. Aspects cliniques et hémodynamiques de Cyclo 3 dans l’insuffisance veineuse. Angiol 1984; 3: 119-22.

  17. Lozes A, Boccalon H. Double-blind study of ruscus extract: venous plethysmographic results. Internat Angiol 1984; 3: 99-102.

  18. Chabanon MR. Action antalgique et decongestive de Cyclo 3 en proctologie. J Médec Lyon 1972; 629-31.

  19. Horning I. Wirkung und Wirkunsmechanismus odemprotektiver substanzen und Modell der Vena auricularis des Schweines und an dem der Katzenextremität. Munich: Dissertation; 1989.

  20. Monograph Rusci aculeati rhizoma. Bundesanzeiger 1991; 12 (7): 127.

  21. Bouskela B. Inhibitory effect of the ruscus extract and the flavonoid hesperidinmethylchalcone on increased microvascular permeability induced by various agents in the hamster cheek pouch. In: P.M. Vanhoutte (Ed.) Return circulation and norepinephrine: an update. Paris: John Libbey; 1991.




2020     |     www.medigraphic.com